MGC Pharmaceuticals Limited
MGCLFOTCHealthcare
$0.27
+$0.01(+2.88%)
Market Cap$12112454
P/E Ratio—
52W High$5.1
52W Low$0.225
MGC Pharmaceuticals Limited (MGCLF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MGCLF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2024Report Date: Apr 30, 2024EPS Actual
-$0.00
Revenue
$0.00B
Fiscal Period
Q2 FY2024
FY ends December
Report Date
Apr 30, 2024
After Market Close
MGCLF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2025 | Feb 26, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 29, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Jul 26, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | Apr 30, 2024 | — | — | — | — | — | — |
| — Q2 FY2024 | Apr 30, 2024 | — | -$0.00 | — | $0.00B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | -$2.17 | — | $0.00B | — | — |
| — Q4 FY2022 | Dec 30, 2022 | — | -$2.59 | — | $0.00B | — | — |
| — Q2 FY2022 | Jun 30, 2022 | — | -$3.25 | — | $0.00B | — | — |
Q1 FY2025
Feb 26, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 29, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Jul 26, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Apr 30, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Apr 30, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023
EPS Actual
-$2.17
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Dec 30, 2022
EPS Actual
-$2.59
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2022
Jun 30, 2022
EPS Actual
-$3.25
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
No analyst estimates available for MGCLF.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2024 | Apr 30, 2024 | — | $0.28 | $0.28 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $4.00 | $4.00 | +0.00% |
| — Q4 FY2022 | Dec 30, 2022 | — | $6.90 | $13.50 | +95.65% |
| — Q2 FY2022 | Jun 30, 2022 | — | $11.00 | $13.60 | +23.64% |
| — Q4 FY2021 | Dec 30, 2021 | — | $28.40 | $28.00 | -1.41% |
| — Q2 FY2021 | Jun 30, 2021 | — | $33.00 | $30.10 | -8.79% |
| — Q4 FY2020 | Dec 30, 2020 | — | $19.00 | $20.00 | +5.26% |
| — Q2 FY2020 | Jun 30, 2020 | — | $30.00 | $30.00 | +0.00% |
Q2 FY2024+0.00%
Report Date
Apr 30, 2024
EPS Beat/Miss
—
Price Before
$0.28
Price After
$0.28
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$4.00
Price After
$4.00
Q4 FY2022+95.65%
Report Date
Dec 30, 2022
EPS Beat/Miss
—
Price Before
$6.90
Price After
$13.50
Q2 FY2022+23.64%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$11.00
Price After
$13.60
Q4 FY2021-1.41%
Report Date
Dec 30, 2021
EPS Beat/Miss
—
Price Before
$28.40
Price After
$28.00
Q2 FY2021-8.79%
Report Date
Jun 30, 2021
EPS Beat/Miss
—
Price Before
$33.00
Price After
$30.10
Q4 FY2020+5.26%
Report Date
Dec 30, 2020
EPS Beat/Miss
—
Price Before
$19.00
Price After
$20.00
Q2 FY2020+0.00%
Report Date
Jun 30, 2020
EPS Beat/Miss
—
Price Before
$30.00
Price After
$30.00
Beat Rate0 / 8 quarters
Largest Move+95.65% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MGCLF ends December
MGC Pharmaceuticals Limited (MGCLF) most recently reported earnings on April 30, 2024 for Q2 FY2024, posting EPS of $-0.00 (in line with the analyst consensus of —). The next MGCLF earnings date is expected around September 1, 2026.
Each quarter, investors track MGCLF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MGCLF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MGCLF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MGCLF earnings · 4 questionsMGC Pharmaceuticals Limited's next earnings report is expected around September 1, 2026. MGCLF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MGCLF historically reports after market close (AMC).
MGCLF earnings datewhen is MGCLF earningsMGCLF next earnings datewhen does MGCLF report earningsMGCLF earnings calendar
▸ Source: FMP · MGC Pharmaceuticals Limited SEC filings · US GAAP · MGC Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026